Celecoxib pathways
- 1 April 2012
- journal article
- pharmgkb summary
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 22 (4), 310-318
- https://doi.org/10.1097/fpc.0b013e32834f94cb
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- PharmGKB summaryPharmacogenetics and Genomics, 2011
- Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal AdenomaGastroenterology, 2009
- 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumorsProceedings of the National Academy of Sciences, 2009
- Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapyBritish Journal of Cancer, 2007
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes MellitusArchives of Internal Medicine, 2005
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000